Repare Therapeutics Q4 2023 Earnings Report
Key Takeaways
Repare Therapeutics reported a decrease in revenue from collaboration agreements for the three-month period ended December 31, 2023, due to lower deferred revenue recognized from the Roche and BMS collaborations. The company's cash, cash equivalents, and marketable securities totaled $223.6 million as of December 31, 2023.
Advanced each of the four programs in its portfolio and set the stage for meaningful data readouts and new clinical trial starts this year.
Presented initial positive data from its ongoing Phase 1 MYTHIC trial evaluating lunresertib alone and in combination with camonsertib.
Announced a partnership with Debiopharm to explore the potential clinical synergy of Debio 0123 and lunresertib.
Dosed the first patient in the multicenter, open-label Phase 1 dose escalation trial of RP-1664 in adult and adolescent patients with TRIM37-high solid tumors in February 2024.
Repare Therapeutics
Repare Therapeutics
Forward Guidance
Repare Therapeutics anticipates several milestones in 2024, including initiating a Phase 1/1b clinical trial of lunresertib and Debio 0123, reporting initial data from multiple trials, disclosing additional camonsertib clinical development plans, and initiating a Phase 1 dose finding trial of RP-3467.
Positive Outlook
- Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123 in the first half of 2024.
- Report initial data from the Phase 1 MINOTAUR trial in the first half of 2024.
- Disclose additional camonsertib clinical development plans in the second quarter of 2024.
- Report data from the dose expansion cohorts of the Phase 1 MYTHIC trial in the second half of 2024.
- Initiation of a Phase 1 dose finding trial of RP-3467 in the second half of 2024.